This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates strong market penetration, successful patient retention, or favorable pricing adjustments, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
This metric represents the total gross revenue generated from the sale of the Yeztugo product line within the company's...
Comparable to specific drug or therapeutic class revenue lines reported by other major biopharmaceutical companies, often benchmarked against market share in the HIV or infectious disease therapeutic categories.
gild_segment_yeztugo_total_revenues| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $0.00 | $166.00M |